In advanced carcinomas, targeting of both αvβ6 and αvβ8 to eliminate the TGFβ producing capacity of the tumour, monocytes, dendritic cells and Tregs, would seem an appropriate future strategy. This evidence concerns the gene TGFB1 and neoplasm.